Summary
Merck & Co., Inc. (MRK) completed a significant merger with Schering-Plough Corporation in November 2009, creating a larger, more diversified pharmaceutical entity. This merger is the defining event for the 2009 fiscal year, impacting the company's operational structure, financial results, and strategic outlook. The combined company benefits from an expanded product portfolio and research and development pipeline, aiming for significant cost synergies and enhanced market presence. Financially, the merger and the sale of the Merial animal health business contributed significantly to the company's results in 2009, including substantial one-time gains. While the company faced challenges such as patent expirations for key products like Cozaar and Hyzaar, the strategic integration and pipeline development signal a focus on long-term growth and a strengthened market position.
Financial Highlights
52 data points| Revenue | $27.43B |
| Cost of Revenue | $9.02B |
| Gross Profit | $18.41B |
| R&D Expenses | $5.84B |
| SG&A Expenses | $8.54B |
| Interest Expense | $460.00M |
| Net Income | $12.90B |
| EPS (Basic) | $5.67 |
| EPS (Diluted) | $5.65 |
| Shares Outstanding (Basic) | 2.27B |
| Shares Outstanding (Diluted) | 2.27B |
Key Highlights
- 1The company completed a merger with Schering-Plough Corporation on November 3, 2009, significantly altering its structure and operations.
- 2Merck reported total revenues of $27.4 billion for 2009, a 15% increase driven largely by the inclusion of Schering-Plough's post-merger results.
- 3Significant one-time gains were recorded in 2009: $7.5 billion from remeasuring its interest in the Merck/Schering-Plough partnership and $3.2 billion from the sale of its interest in Merial Limited.
- 4The company announced a global restructuring program in February 2010 to optimize the cost structure of the combined entity, including a workforce reduction of approximately 15%.
- 5Key products like Singulair, Januvia, and Isentress showed strong sales growth, contributing positively to the financial results.
- 6Several major products, including Cozaar and Hyzaar, are expected to face patent expirations in 2010, with Singulair's patent expiration in the U.S. anticipated in August 2012.
- 7The company is managing substantial ongoing litigation, most notably related to Vioxx, with significant settlements and reserves established.